# Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

> **NCT01651104** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 63 (actual)

## Conditions studied

- Human Influenza

## Interventions

- **BIOLOGICAL:** Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)

## Key facts

- **NCT ID:** NCT01651104
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01651104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01651104, "Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01651104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*